MEDICAL-USE UPDATE: As of May 18, 2021, 36 states and fourĀ territories allow for the medical use of cannabis products.
In November 2020, voters in Mississippi passed a ballot initiative to allow for medical use, but it was overturned by the state supreme court on May 14, 2021, and is not counted in the state totals on this page. Please see Table 1 for more information.Ā
NONMEDICAL/ADULT-USE UPDATE: As of June 22, 2021, 18Ā states, two territories and the District of Columbia have enacted legislation to regulate cannabis for nonmedicalĀ use.
- Voters in Arizona, Montana, New JerseyĀ and South Dakota approved measures to regulate cannabis for nonmedicalĀ use.
- On Feb.Ā 8, 2021, South Dakota Circuit Judge Christina Klinger ruled that the measure was unconstitutional. The decision is being appealed as of March 31, 2021.
- New Jersey’s governor signed enacting legislation on March 1, 2021.
- New York’s legislature and governor enacted AB 1248/SB 854 on March 31, 2021.
- The Virginia General AssemblyĀ passedĀ legislation on Feb.Ā 27 and approved the governor’s amendments on April 7, 2021.
- The New Mexico legislature passed legislationĀ on March 31 and the governor signed itĀ on April 12, 2021.
- The Connecticut General AssemblyĀ passedĀ SB 1201Ā on June 17Ā and the governor signed it on June 22, 2021.
- These actions bring the number of states with nonmedical (adult-use) regulated cannabis to 18, plus two territories and the District of Columbia (D.C. does not regulate nonmedical sales).
- This total does NOTĀ includeĀ South Dakota’s court-over-turnedĀ measure, which is pending appeal.Ā Ā
Please see Table 1 below for more information.
A total of 36Ā states, the District of Columbia,Ā Guam,Ā Puerto Rico and the U.S. Virgin IslandsĀ have approved comprehensive, publicly available medical marijuana/cannabis programs.
Please see Table 1 below for more information.
Approved measuresĀ in 11Ā states allow the use of “low THC, high cannabidiol (CBD)” products forĀ medical reasonsĀ in limited situations or as a legal defense.Ā (See Table 2 below for more information). Low-THCĀ programs are not counted as comprehensive medical cannabisĀ programs. NCSL uses criteria similar to other organizations tracking this issue to determine if a program is “comprehensive”:
- Protection from criminal penalties for using cannabisĀ for a medical purpose.
- Access to cannabisĀ through home cultivation,Ā dispensaries or some other system that is likely to be implemented.
- It allows a variety of strains or products, including those with more than “low THC.”
- It allows either smoking or vaporization of some kind of cannabisĀ products,Ā plant material or extract.
- Is not a limited trial program.Ā (Nebraska hasĀ aĀ trial programĀ that isĀ not open to the public.)
April 14, 2021: South Dakota’s overturned nonmedical (adult-use) ballot measure is currently under appealĀ as of March 11, 2021.
* = 2020 measures in Mississippi for medical use and South Dakota for nonmedical use were overturned in 2021.
Please see Table 1 below for more information.
Medical Uses of Cannabis
In response to California’s Prop 215, the Institute of MedicineĀ issuedĀ aĀ reportĀ that examinedĀ potential therapeutic uses for cannabis.Ā The report found that: “Scientific data indicate the potential therapeutic value of cannabinoid drugs, primarily THC, for pain relief, control of nausea and vomiting, and appetite stimulation; smoked marijuana, however, is a crude THC delivery system that also delivers harmful substances. The psychological effects of cannabinoids, such as anxiety reduction, sedation, and euphoria can influence their potential therapeutic value. Those effects are potentially undesirable for certain patients and situations and beneficial for others. In addition, psychological effects can complicate the interpretation of other aspects of the drug’s effect.”
Further studies have found that marijuana is effective in relieving some of the symptoms of HIV/AIDS, cancer, glaucoma, and multiple sclerosis.1 Ā
In early 2017, theĀ National Academies of Sciences, Engineering, and Medicine released a reportĀ based on the review of over 10,000 scientific abstracts from cannabisĀ health research. They also madeĀ 100 conclusionsĀ related to health and suggestĀ ways to improve cannabis research.
State vs Federal Perspective
At the federal level, cannabisĀ remains classified as a Schedule I substance under theĀ Controlled Substances Act, where ScheduleĀ I substances are considered to have a high potential for dependency and no accepted medical use, making distribution of cannabisĀ a federal offense. In October of 2009, the Obama Administration sent a memo to federal prosecutors encouraging them not to prosecute people who distribute cannabisĀ for medical purposes in accordance with state law.
In late August 2013, theĀ U.S. Department of Justice announced an update to their marijuana enforcement policy.Ā The statement readĀ that while cannabisĀ remains illegal federally, the USDOJ expects states like Colorado and Washington to create “strong, state-based enforcement efforts…. and will defer the right to challenge their legalization laws at this time.” The department also reserves the right to challenge the states at any time they feel it’s necessary.
More recently, in January 2018, former Attorney General Sessions issued a Marijuana Enforcement Memorandum that rescinded the Cole Memorandum, and allows federal prosecutors to decide how to prioritize enforcement of federal cannabisĀ laws. Specifically, the Sessions memorandum directs U.S. Attorneys to āweigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community.ā Text of the memo can be found here:Ā https://www.justice.gov/opa/pr/justice-department-issues-memo-marijuana-enforcement
NCSL’s policy on state cannabis laws can be found underĀ Additional Resources below.
Arizona and the District of Columbia voters passed initiatives to allow for medical use, only to have them overturned. In 1998, voters in the District of Columbia passedĀ Initiative 59. However, Congress blocked the initiative from becoming law. In 2009, Congress reversed its previous decision, allowing the initiative to become law. The D.C. Council then put Initiative 59 on hold temporarily and unanimously approved modifications to the law.
Before passing Proposition 203 in 2010, Arizona voters originally passed a ballot initiative in 1996. However, the initiative stated that doctors would be allowed to write a “prescription” for cannabis. Since cannabis isĀ a Schedule I substance, federal law prohibits its prescription,Ā making the initiative invalid.Ā Medical cannabis “prescriptions” are more often called “recommendations” or “referrals” because of the federal prescription prohibition.
States with medical cannabisĀ laws generally have some form of patient registry, which may provide someĀ protection against arrest for possession up to a certain amount of products for personal medicinal use.
SomeĀ of theĀ most common policyĀ questions regarding medical cannabisĀ include how to regulate its recommendation, dispensing, and registration of approved patients.Ā Some small cannabis growers orĀ are often called “caregivers” and may grow a certain number of plants per patient.Ā This issue may also be regulated on a local level, in addition to any state regulation.
| State (click stateĀ name to jump to program information) | Statutory Language (year | Patient Registry or ID cards | Allows Dispensaries | Specifies Conditions | Recognizes Patients from other states | State Allows for Retail Sales/Nonmedical (Adult) Use |
|---|---|---|---|---|---|---|
| Alabama | SB46Ā (2021) | Yes | Yes | Yes | No | |
| Alaska | Measure 8Ā (1998)Ā SB 94Ā (1999)Ā Statute Title 17, Chapter 37 | Yes | Yes | Yes | No, but adults 21 and older may purchase at nonmedical retail dispensaries. | Ballot Measure 2Ā (2014)Ā Marijuana Regulations |
| Arizona | Proposition 203Ā (2010) | Yes | Yes | Yes | Yes, for AZ-approved conditions, but not for dispensary purchases. | Proposition 207Ā (2020) |
| Arkansas | Issue 6Ā (2016) | Yes | Yes | Yes | Yes | |
| California | Proposition 215Ā (1996)Ā Ā SB 420Ā (2003) | Yes | Yes (cooperatives and collectives) | No | No | Proposition 64 (2016) |
| ColoradoĀ Ā Ā Medical program infoĀ Ā -Nonmedical use info | Amendment 20Ā (2000) | Yes | Yes | Yes | No | Amendment 64Ā (2012)Ā Task ForceĀ ImplementationĀ RecommendationsĀ (2013) Analysis of CO Amendment 64Ā (2013) Colorado Marijuana Sales andĀ Tax ReportsĀ 2014 “Edibles” regulationĀ measureĀ FAQ about CO cannabis laws by the Denver Post.Ā |
| Connecticut | HB 5389Ā (2012) Nonmedical use legislationĀ SB 1201Ā (2021) | Yes | Yes | Yes | SB 1201Ā (2021) | |
| Delaware | SB 17Ā (2011) | Yes | Yes | Yes | Ā Yes, for DE-approved conditions. | |
| District of Columbia | Initiative 59Ā (1998) Ā L18-0210Ā (2010) | Yes | Yes | Yes | Initiative 71Ā (2014) | |
| Florida | Amendment 2Ā (2016) | Yes | Yes | Yes | No | |
| Guam | Proposal 14AĀ Approved in Nov. 2014, fullyĀ operational.- home growing currently allowed until dispensaries openĀ Draft rulesĀ released in July 2015Ā Ā Nonmedical use-Ā 2019 Bill No. 32-35Ā signed by governor in April, 2019 | Yes | Yes | Yes | No | Yes. Nonmedical use-Ā 2019 Bill No. 32-35Ā signed by governor in April, 2019 |
| Hawaii | SB 862Ā (2000) | Yes | Yes | Yes | No | |
| Illinois | HB 1Ā (2013)Ā Eff. 1/1/2014Ā Rules Nonmedical use legalizationĀ SB 0007Ā bill passed legislature May, 2019, signed by governor June 25, 2019, Effective Jan. 1, 2020. | Yes | Yes | Yes | No | Measure approved by legislatureĀ in May, 2019, signed by governor June 25, 2019. Effective Jan. 1, 2020. |
| Louisiana | SB 271Ā (2017) (not yet in effect) | No | Yes | Yes | No | |
| Maine | Question 2Ā (1999)Ā Ā LD 611Ā (2002)Ā Ā Ā Question 5Ā (2009)Ā Ā Ā LD 1811Ā (2010)Ā LD 1296Ā (2011) | Yes | Yes | Yes | Yes, but not for dispensary purchases. Adults 21 and older may purchase from nonmedical retail dispensaries. | Question 1Ā (2016) page 4Ā Chapter 409 (2018) |
| Maryland | HB 702Ā (2003)Ā SB 308Ā (2011)Ā HB 180/SB 580Ā (2013)Ā Ā HB 1101-Ā Chapter 403Ā (2013)Ā SB 923Ā (signed 4/14/14) HB 881- similar to SB 923 | Yes | Yes | Yes | No | |
| Massachusetts | Question 3Ā (2012) RegulationsĀ (2013) | Yes | Yes | Yes | No | Question 4Ā (2016) |
| Michigan | Proposal 1Ā (2008) | Yes | Yes | Yes | Yes, for legal protection of possession, but not for dispensary purchases. Adults 21 and older may purchase from nonmedical retail dispensaries. | Proposal 18-1 (2018) |
| Minnesota | SF 2471, Chapter 311 (2014) | Yes | Yes, limited, liquid extract products only | Yes | No | |
| Mississippi *overturned May 14, 2021 | Initiative 65 (2020) News:Ā Mississippi Supreme Court Overturns Medical Marijuana Amendment 65 | |||||
| Missouri | Amendment 2 (2018) | Yes | Yes | Yes | Yes | |
| Montana | Initiative 148Ā (2004)Ā SB 423Ā (2011) Initiative 182Ā (2016) | Yes Yes | YesĀ Yes | Yes Ā Yes | No | Initiative 190Ā (2020) |
| Nevada | Question 9Ā (2000)Ā NRS 453AĀ NAC 453A | Yes | Yes | Yes | Yes, if the other state’s program are “substantially similar.” Patients must fill out Nevada paperwork. Adults 21 and older may purchase at nonmedical retail dispensaries. | Question 2Ā (2016) page 25 |
| New Hampshire | HB 573Ā (2013) HB 89Ā (2021) | Yes | Yes | Yes | Yes, with a note from their home state, but they cannot purchase through dispensaries. | |
| New Jersey | SB 119Ā (2009) Program information | Yes | Yes | Yes | No | Public Question 1Ā passed by voters in 2020 to allow legislature to enact legislation NJ AB 21Ā passed legislature, signed by governor March 1, 2021 |
| New Mexico | SB 523Ā (2007) Medical Cannabis Program | Yes | Yes | Yes | No | HB 2Ā Cannabis regulation act passed legislature March 31, 2021 and signed by governor on 4/12/21. |
| New York | A6357Ā (2014) Signed by governor 7/5/14 | Yes | Yes- Ingested doses may not contain more than 10 mg of THC, product may not be combusted (smoked). | Yes | No | AB 1248A/SB 854Ā passed legislature, signed by governor on March 31, 2021. |
| North Dakota | Measure 5Ā (2016)Ā NDCC 19-24.1Ā NDAC 33-44 | Yes | Yes | Yes | No | |
| Northern Mariana Islands | Does not have a medical program. | Yes, HB 20-178 HD 4- Public Law 20-66 (2018) | ||||
| Ohio | HB 523Ā (2016) Approved by legislature, signed by governor 6/8/16 | Yes | Yes | Yes | Yes- If approved by the Board of Pharmacy on a state-by-state basis. | |
| Oklahoma | SQ 788Ā Approved by voters on 6/26/18 | Yes | Yes | Yes, but list was not included in the initial ballot measure. | Yes but must apply as a temporary patient | |
| Oregon | Oregon Medical Marijuana ActĀ (1998)Ā SB 161Ā (2007) | Yes | Yes | Yes | No, but adults over 21 may purchase at adult retail dispensaries. | Measure 91Ā (2014) |
| Pennsylvania | SB 3Ā (2016) Signed by governor 4/17/16 | Yes | Yes | Yes | No | |
| Puerto Rico | Public Health DepartmentĀ Regulation 155Ā (2016) in Spanish | Yes | Yes- Cannot be smoked | Yes | Yes | |
| Rhode Island | S 710 BĀ (2006)- Legislature overturned governor’s veto. SB 791Ā (2007)Ā Ā SB 185Ā (2009) | Yes | Yes | Yes | Yes | |
| South Dakota *Nonmedical measure ruled unconstitutional as of Feb. 9, 2021. | Initiated Measure 26 (2020) News:Ā Court rules measure unconstitutional Feb. 8, 2021 | Yes | Yes | Yes | Yet to be determined | Amendment AĀ (2020) OVERTURNED BY COURTS Feb. 8, 2021 NOT COUNTED IN STATE TALLY ABOVE |
| US Virgin Islands | SB 135Ā (2017) signed by governor 1/19/19 | |||||
| Utah | Prop 2 (2018)Ā replaced by HB 3001Ā HB 3001 2018– Third Special Session | Yes | Yes | Yes | Yes | |
| Vermont | SB 76Ā (2004)Ā SB 7Ā (2007)Ā SB 17Ā (2011)Ā H.511Ā (2018) | Yes | Yes | Yes | No, but adults 21 years old and older may purchase from the nonmedical market. | H.511Ā approved by legislature, signed byĀ governor 1/22/18. Effective July 1, 2018. S.54Ā (2020) establishes sales regulations. Effective Oct. 7, 2020. Governor’s letterĀ re: S. 54, going into effect without his signature.Ā Ā Additional info: Governor’s Marijuana Advisory Commission Final Report- December, 2018 |
| Virginia | H 1460 (2020) | Yes | Yes | No | No, but allows for temporary residents to apply with approval from the Board of Pharmacy. | Yes, legislature approvedĀ HB2312Ā andĀ SB1406.Ā Signed by governor 4/7/21. |
| Washington | Initiative 692(1998)Ā SB 5798Ā (2010)Ā SB 5073Ā (2011) | Registry is voluntary. | Yes, approved as of Nov. 2012, stores opened in July, 2014. | Yes | No, but adults 21 and older may purchase at nonmedical retail dispensaries. | Initiative 502Ā (2012) WAC Marijuana rules: Chapter 314-55 WAC FAQ about WA cannabis lawsĀ by the Seattle Times. |
| West Virginia | SB 386 (2017) | Yes | Yes. No whole flower/cannot be smoked but can be vaporized. | Yes | No, but may allow their patients who are terminally ill to buy in other states. WV does not recognize other state cards. |
*The linksĀ and resources are provided for information purposes only. NCSL does not endorse the views expressed in any of the articles linked from this page.
| State | Program Name andĀ Statutory Language (year) | Patient Registry or ID cards | Dispensaries or Source of Product(s) | Specifies Conditions | Recognizes Patients from other states | Definition of Products Allowed | Allows for Legal Defense | Allowed for Minors |
|---|---|---|---|---|---|---|---|---|
| AlabamaĀ (SB46 of 2021 created aĀ new medical cannabis law enacted on May 17, 2021 and isĀ listed in Table 1.)Ā Ā | SB 174 “Carly’s Law”Ā (Act 2014-277) Allows University of Alabama Birmingham to conduct effectivenessĀ research usingĀ low-THC products forĀ treating seizure disorders for up to 5 years.Ā Ā HB 61Ā (2016) Leni’s Law allows more physicians to refer patients to use CBD for more conditions. | No | Provides legal defense for possession and/or use of CBD oil. Ā Does not create an in-stateĀ production method. | Yes, debilitating epileptic conditions,Ā life-threatening seizures, wasting syndrome, chronic pain, nausea, muscle spasms, any other sever condition resistant to conventional medicine. | No | Extracts that are low THC= below 3% THC | Yes | Yes |
| Florida (NEW comprehensive program approved in 2016, included in table above) | Compassionate Medical Cannabis Act of 2014Ā CS for SB 1030 (2014)Ā Patient treatment information and outcomes will be collected and used for intractable childhood epilepsy research | Yes | Yes, 5 registered nurseries across the state by region, which have been in business at least 30 years in Florida. | Yes, cancer, medical condition or seizure disorders that chronically produces symptoms that can be alleviated by low-THC products | No | Cannabis with low THC= below .8% THC and above 10% CBD by weight | Yes, with approval from 2 doctors | |
| Georgia | HB 1 (2015)Ā (signed byĀ governorĀ 4/16/15) | Yes | Law allows University System of Georgia to develop a lot THC oil clinical research program that meets FDA trial compliance. | Yes, end stage cancer, ALS, MS, seizure disorders, Crohn’s, mitochondrial disease, Parkinson’s, Sickle Cell disease | No | Cannabis oils with low THC= below 5% THC and at least an equal amount of CDB. | Yes | Yes |
| Ā Idaho- VETOED BY GOVERNOR | SB 1146Ā (VETOED by governorĀ 4/16/15) | No | Doesn’t define. | The possessor has, or is a parent or guardian of a person thatĀ has, cancer, amyotrophic lateral sclerosis, seizure disorders,Ā multiple sclerosis, Crohn’s disease, mitochondrial disease, fibromyalgia, Parkinson’s disease or sickle cell disease; | No | Is composed of no more than three-tenths percent (0.3%)Ā Ā tetrahydrocannabidiol by weight; Ā is composed of at least fifteen (15) times more cannabidiolĀ than tetrahydrocannabidiol by weight; andĀ contains no other psychoactive substance. | Yes | Yes |
| Indiana | HB 1148Ā (2017) | Yes | Doesn’t define. | Treatment resistant epilepsy. | No | At least 5 percent CBD by weight. No more than .3 percent THC by weight. | Yes | Yes |
| Iowa | SF 2360, Medical Cannabidiol Act of 2014Ā (Effective 7/1/14 and repealed in 2017 and replaced) HF 524Ā of 2017 nowĀ Section 124E | Yes | Yes | Yes | Yes, for possession or use only, not for purchasing CBD in Iowa. | Less than 3 percent THC | Yes | Yes |
| Kentucky | SB 124Ā (2014)Ā Clara Madeline Gilliam Act Exempt cannabidiol from the definition of marijuana and allows it to be administered by a public university or school of medicine in Kentucky for clinical trial or expanded access program approved by the FDA. | No | Universities in Kentucky with medical schools that are able to get a research trial. Doesn’t allow for in-state production of CBD product. | Intractable seizure disorders | No | No, only “cannabidiol”. | ||
| Mississippi (Overturned Amendment 65 from 2020 included in table above.) | HB 1231Ā “Harper Grace’s Law” 2014 | All provided through National Center for Natural Products Research at the Univ. of Mississippi and dispensed by the Dept. of Pharmacy Services at the Univ. of Mississippi Medical Center | Yes, debilitating epileptic condition or related illness | No | “CBD oil” – processed cannabis plantĀ extract, oil or resin that contains more than 15% cannabidiol, or a dilution of the resin that contains at least 50 milligrams of cannabidiol (CBD) per milliliter, but not more than one-half of one percent (0.5%) of tetrahydrocannabinol (THC) | Yes, if an authorized patient or guardian | Yes | |
| MissouriĀ Ā (NEW comprehensive program approved in 2018, included in table above) | HB 2238Ā (2014) | Yes | Yes, createsĀ cannabidiol oil care centers and cultivation and production facilities/laboratories. | Yes, intractable epilepsy that has not responded to three or more other treatment options. | No | “Hemp extracts” equal or less than .3% THC and at least 5% CBD by weight. | Yes | Yes |
| North Carolina | HB 1220Ā (2014) Epilepsy Alternative Treatment Act- Pilot StudyĀ HB 766Ā (2015) Removes Pilot Study designation | Yes | University research studies with a hemp extract registration card from the state DHHS or obtained from another jurisdiction that allows removal of the products from the state. | Yes, intractable epilepsy | No | “Hemp extracts” with less than nine-tenths of one percent (0.9%) tetrahydrocannabinol (THC) by weight. Is composed of at least fiveĀ percent (5%) cannabidiol by weight. Contains no other psychoactive substance. | Yes | Yes |
| OklahomaĀ (NEW comprehensive medical program approved in 2018 and listed above) | Ā HB 2154Ā (2015) | Yes | No in-state production allowed, so products would have to be brought in. Any formal distribution system would require federal approval. | People under 18 (minors)Ā Minors with Lennox-Gastaut Syndrome, Dravet Syndrome, or other severe epilepsy that is not adequately treated by traditional medical therapies | No | A preparation of cannabis with no more than .3% THC in liquid form. | Yes | Yes, only allowed for minors |
| South Carolina | Ā SB 1035Ā (2014) Medical Cannabis Therapeutic Treatment Act- Julian’s Law | Yes | Must use CBD product from an approved source; and (2)Ā Ā approved by the United States Food and Drug Administration to be used for treatment of a condition specified in an investigational new drug application. -The principal investigator and any subinvestigator may receive cannabidiol directly from an approved source or authorized distributor for an approved source for use in the expanded access clinical trials. Some have interpreted the law to allow patients and caregivers to produce their own products. | Lennox-Gastaut Syndrome, Dravet Syndrome, also known as severe myoclonic epilepsy of infancy, or any other form of refractory epilepsy that is not adequately treated by traditional medical therapies. | No | Cannabidiol or derivative of marijuana that contains 0.9% THC and over 15% CBD, orĀ least 98 percent cannabidiol (CBD) and not more than 0.90%Ā tetrahydrocannabinol (THC)Ā by volume that has been extracted from marijuana or synthesized in a laboratory | Yes | Yes |
| Tennessee | SB 2531Ā (2014) Creates a four-year study of high CBD/low THC cannabisĀ at Tenn.Ā Tech Univ.
| Researchers need to track patient information and outcomes | Only products produced by Tennessee Tech University. Patients may possess low THC oils only if they are purchased “legally in the United States and outside of Tennessee,” from an assumed medical cannabis state, howeverĀ most states do not allow products to leave the state. | Yes, intractable seizure conditions.
| No
| “Cannabis oil” withĀ less than .9% THC as part of a clinical research study.
| Yes | Yes |
| HB 197Ā (2015) | No | Allows for legal defense for having the product as long as it was obtained legally in the US or other medical cannabis state. | Yes, intractable seizure conditions. | No | Same as above. | Yes | Yes | |
| Texas | SB 339Ā (2015) Texas Compassionate Use ActHB 3703Ā (2019) | Yes | Yes, licensed by the Department of Public Safety. | Yes, intractable epilepsy, incurable neurodegenerative disease, terminal cancer, multiple sclerosis, spasticity, ALS, autism. | No | “Low-THC Cannabis” with not more than 0.5 percent by weight of tetrahydrocannabinols. | Yes | Yes |
| UtahĀ (NEW comprehensive program approved in 2018,Ā included in table above) | HB 105Ā (2014) Hemp Extract Registration Act | Yes | Not completely clear, however it may allowĀ higher education institutions to grow or cultivate industrial hemp. | Yes, intractable epilepsy that hasn’t responded to three or more treatment options suggested by a neurologist. | No | “Hemp extracts” with less than .3% THC by weight and at least 15% CBD by weight and contains no other psychoactive substances | Yes | Yes |
| Ā Virginia (NEW comprehensive medical program approved in 2020Ā and listed above) | HB 1445– no longer in effect | No | No in-state means of acquiring cannabis products. | Intractable epilepsy | No | Cannabis oils with at least 15% CBD or THC-A and no more than 5% THC. | Yes | Yes |
| Wisconsin | AB 726 (2013 Act 267) | No | Physicians and pharmacies with an investigational drug permit by the FDA could dispense cannabidiol. Qualified patients would also be allowed to access CBD from an out-of-state medical cannabis dispensary that allows for out-of-state patients to use their dispensaries as well as remove the products from the state. No in-state production/manufacturing mechanism provided. | Seizure disorders | Exception toĀ the definition of prohibited THC by state law, allows for possession of “cannabidiol in a form without a psychoactive effect.” Ā THC or CBD levels are not defined. | No | Yes | |
| Wyoming | HB 32 (2015) Supervised medical use of hemp extracts. Effective 7/1/2015 | Yes | No in-state production or purchase method defined. | Intractable epilepsy or seizure disorders | No | “Hemp extracts” with less than 0.3% THC and at least 5% CBD by weight. | Yes | Yes |
*The linksĀ and resources are provided for information purposes only. Ganjly does not endorse the views expressed in any of the articles linked to this page.
Reprinted from Source: National Conference of State Legislatures
Additional Resources
- NCSL’s Cannabis & Employment LawsĀ page.
- NCSL’s Marijuana Deep Dive pageĀ featuring marijuana and cannabis laws on criminal justice, health and other resources.
- NCSL FY 2018 letter the LCJPS Committee sent to the HillĀ opposing the withholding of funding for state with medical marijuana laws:NCSL FY 2018 CJS Appropriations Support Letter.Ā (May 16, 2017)
- State Marijuana Policy covered in Episode 4 of NCSLās podcast,Ā Our American States.
You can find itĀ on our websiteĀ or subscribe to the podcast inĀ iTunes,Ā Google PlayĀ or your favorite podcast app. - Comparisons of programs
- Comparison of all state medical marijuana programs with contact information. Prepared by the Network for Public Health Law as of Feb. 2019Ā
- Comparison of state limited access medical marijuana programs. Prepared by the Network for Public Health Law as of June 2018.
- “State-by-State Medical Marijuana Laws”Ā Marijuana Policy Project, 2019
- Finances/Tax information
- Regulating Marijuana: Taxes, Banking and Federal Laws, November 2015
- “State Medical Marijuana Programs’ Financial Information,” Marijuana Policy Project, July 2015
- “Medical Marijuana Dispensary Laws: Fees and Taxes,” Marijuana Policy ProjectĀ
- Colorado Marijuana Sales andĀ Tax ReportsĀ (updated monthly)
- Washington State Sales and Tax Information (updated weekly)
- “Taxing Marijuana: The Washington and Colorado Experience,” Tax Foundation, August 2014
- Law enforcement/crime information
- “What Law Enforcement Can Learn from Marijuana Legalization in Colorado,” Prepared by American Military University, March, 2015
- Statement by ONDCP Director Gil Kerlikowske regarding Federal guidelines for medical marijuana prosecution
- Medical marijuana research and reports
- The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, 2017
- “Marijuana and Medicine: Assessing the Science Base,” Institute of Medicine, 1999
- “Exposing the Myth of Smoked Medical Marijuana,” U.S. Drug Enforcement Administration
- Treatment Research Institute’s (TRI) policy position statement regarding medical marijuana
- ProCon.org’s resources on medical marijuana. Medical Marijuana ProCon.org presents laws, studies, statistics, surveys, government reports, and pro and con statements on questions related to marijuana as medicine
- “Becoming a State-Authorized Patient,” Americans for Safe Access
- Nonmedical/Adult Use information and news
- Regulating Marijuana: Taxes, Banking and Federal Laws, November 2015
- Regulating Marijuana: A Year and a Half In, NCSL, October 2015
- “State Legalization ofĀ RecreationalĀ Marijuana: Selected Legal Issues.” Congressional Research Service, April 2013
- Analysis of CO Amendment 64 (rec use initiative)Ā by Colorado State University, April 2013
- Colorado Marijuana Sales andĀ Tax Reports
- Colorado Marijuana Enforcement Division Annual Update, February 2015
- Public Health Law Research Law Atlas: Ā Recreational Marijuana Laws – Interactive Map
- Public health and youth information
- Marijuana Joins Smoke-Free Laws,Ā State Legislatures, March 2013
- Regulating Recreational Use of Marijuana and the Role of Public Health LawĀ Prepared by the Network for Public Health Law
- Marijuana Impact on Public Health and Safety in Colorado: conference by CO Association of Chiefs of Police, January 14-16, 2015
- Smart Colorado: Protecting youth from marijuana
- Interest groups,Ā position statements, opinions, andĀ model regulation examples
- SAM: Smart Approaches to Marijuana
- Smart Colorado: Protecting youth from marijuana
- Resources from theĀ Public Health Institute
- Treatment Research Institute’s (TRI) policy position statement regarding medical marijuana
- National Families in Action: Marijuana Studies Program “Marijuana Report”
- “Medical Cannabis as a Tool to Combat Pain and the Opioid Crisis: A Blueprint for State Policy”Ā Americans for Safe Access
- “State-by-State Medical Marijuana Laws”Ā Marijuana Policy Project, 2016
- “Key Aspects of State and DC Medical Marijuana Laws,”Ā Marijuana Policy ProjectSave
- “Becoming a State-Authorized Patient,” Americans for Safe Access
- Brookings Institution:Ā Colorado’s Rollout of Legal Marijuana Is Succeeding



